Expert Review of Neurotherapeutics最新文献_第4页

The value of hypothermia as a neuroprotective and antiepileptic strategy in patients with status epilepticus: an update of the literature. 低体温作为神经保护和抗癫痫策略对癫痫状态患者的价值：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-11-24 DOI: 10.1080/14737175.2024.2432869

Stéphane Legriel, Candice Fontaine, Gwenaelle Jacq

引用次数: 0

Tackling persistent neurological symptoms in patients following acute COVID-19 infection: an update of the literature. 应对急性COVID-19感染后患者持续的神经系统症状：文献更新

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-23 DOI: 10.1080/14737175.2024.2440543

Eder Cáceres, Afshin A Divani, Andre Emilio Viñan-Garces, Juan Olivella-Gomez, Alejandro Quintero-Altare, Sebastián Pérez, Luis F Reyes, Nicholas Sasso, Jose Biller

{"title":"Tackling persistent neurological symptoms in patients following acute COVID-19 infection: an update of the literature.","authors":"Eder Cáceres, Afshin A Divani, Andre Emilio Viñan-Garces, Juan Olivella-Gomez, Alejandro Quintero-Altare, Sebastián Pérez, Luis F Reyes, Nicholas Sasso, Jose Biller","doi":"10.1080/14737175.2024.2440543","DOIUrl":"10.1080/14737175.2024.2440543","url":null,"abstract":"Introduction: The COVID-19 pandemic has taught myriad lessons and left several questions we are yet to comprehend. Initially, the scientific community was concerned with the management of acute disease and immunization. Once the peak of the pandemic receded, it became clear that a proportion of patients were far from fully recovered. Researchers started to recognize those persisting symptoms as a new entity termed 'Long COVID,' where neurological symptoms are evident and have a major impact on quality of life.Areas covered: The main purpose of this narrative review is to analyze and synthesize the current literature regarding Long COVID, its relation to the nervous system, and to explore the evidence on treatments for persistent neurological symptoms. The most common reported and observed neurologic manifestations include fatigue, cognitive impairment, pain, polyneuropathy, and neuropsychiatric disorders. A variety of pharmacologic and non-pharmacologic therapies have been evaluated and yielded mixed results. Many of them focused on immunomodulation and none currently have U.S. FDA approval.Expert opinion: Challenges remain in terms of clinical characterization and prognosis of Long COVID, besides understanding its pathophysiology. Standardization of biomarkers and diagnostic criteria will allow the use of common nomenclature and data elements in the design of future clinical studies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"67-83"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease. 布雷克哌唑口服片剂是首款获准用于治疗阿尔茨海默病引起的痴呆症相关躁动症状的药物，对该药物进行了严格审查。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-09-29 DOI: 10.1080/14737175.2024.2407836

Kate Zhong, Jeffrey Cummings

{"title":"A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease.","authors":"Kate Zhong, Jeffrey Cummings","doi":"10.1080/14737175.2024.2407836","DOIUrl":"10.1080/14737175.2024.2407836","url":null,"abstract":"Introduction: Agitation is a common and disruptive syndrome in dementia due to Alzheimer's disease (AD). Brexpiprazole was recently approved for this agitation of AD dementia and is the only therapy approved for this indication.Areas covered: The authors review the chemistry, pharmacokinetics, mechanism of action, and pharmacodynamics of brexpiprazole. Phase 2/3 and Phase 3 studies of brexpiprazole for the treatment of agitation in dementia due to AD are described. These studies demonstrated efficacy and safety for the 2 mg/d and 3 mg/d doses. Agitation reduction from baseline was significantly greater in the active treatment groups compared to the participants on placebo as measured by the Cohen-Mansfield Agitation Inventory, the primary outcome. Treatment benefit was demonstrated on the Clinician Global Impression - Severity, the key secondary outcome. Safety and tolerability were comparable in drug and placebo arms of the studies.Expert opinion: Approval by the Food and Drug Administration (FDA) of brexpiprazole for the treatment of agitation in dementia due to AD is an important milestone and regulatory precedent. This is the first approval for the treatment of any neuropsychiatric syndrome of AD. Brexpiprazole has a 'black box' warning for its use in psychosis caused by dementia due to an observed increase in mortality when using this class of antipsychotic agents in patients with dementia. Post-marketing surveillance will be key to understanding the safety profile of brexpiprazole. Brexpiprazole may be prioritized over the 'off label' use of other potential treatments for agitation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"5-13"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Essential tremor - drug treatments present and future. 原发性震颤-药物治疗的现在和未来。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1080/14737175.2024.2439514

Hortensia Alonso-Navarro, Elena García-Martín, José A G Agúndez, Félix Javier Jiménez-Jiménez

{"title":"Essential tremor - drug treatments present and future.","authors":"Hortensia Alonso-Navarro, Elena García-Martín, José A G Agúndez, Félix Javier Jiménez-Jiménez","doi":"10.1080/14737175.2024.2439514","DOIUrl":"10.1080/14737175.2024.2439514","url":null,"abstract":"Introduction: The main treatment options for essential tremor (ET), which is probably one of the most common movement disorders, have been propranolol and primidone, for many years. This review aims to synthesize therapeutic attempts with other drugs.Areas covered: We have reviewed the current state of the pharmacological treatment of ET, both in patients and in experimental models of this disease, with special emphasis on the data published in the last 5 years. Based on the results in experimental models of ET, proposals have been made for future alternative therapeutic options.Expert opinion: The use of drugs other than propranolol and primidone has not shown a greater degree of efficacy than these in the treatment of ET, although according to certain evidence-based guidelines topiramate and phenobarbital could be alternative drugs. The results on the effectiveness of other drugs have been variable. For patients with refractory ET, especially those with head tremor, local injections with botulinum toxin A may be useful. According to the results of various experimental models, T calcium channel blockers, modulators of GABAA receptors (GABAARs), GABAB receptors (GABABRs), and glutamatergic neurotransmission, and drugs that decrease the expression of LINGO-1 could be interesting options for the future, among others.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"43-56"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Promising therapeutic strategies for Lennox-Gastaut syndrome: what's new? lenox -胃综合征有前景的治疗策略：有什么新进展？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-21 DOI: 10.1080/14737175.2024.2439512

Frank M C Besag, Michael J Vasey, Richard J Brown

{"title":"Promising therapeutic strategies for Lennox-Gastaut syndrome: what's new?","authors":"Frank M C Besag, Michael J Vasey, Richard J Brown","doi":"10.1080/14737175.2024.2439512","DOIUrl":"10.1080/14737175.2024.2439512","url":null,"abstract":"Introduction: The seizures in Lennox-Gastaut syndrome are typically resistant to treatment. Seven antiseizure medications (ASMs) in the US (six in the UK/EU) are licensed for the treatment of seizures in LGS: lamotrigine, topiramate, rufinamide, clobazam, felbamate (not licensed in the UK/EU), cannabidiol and fenfluramine. Other options include neurostimulation, corpus callosotomy and dietary therapies, principally the ketogenic diet and its variants. New treatments and therapeutic strategies are needed to improve management of both seizures and cognitive/behavioral comorbidities in LGS.Areas covered: Embase and Medline were searched for articles published between 1 January 2014 and 21 August 2024 reporting efficacy data for pharmacological, neurostimulation, surgical and dietary interventions in individuals with LGS focusing on recent advances. Ongoing and prospective studies were identified from the National Library of Medicine register of clinical trials.Expert opinion: LGS remains a difficult-to-treat epilepsy. Although no major breakthroughs have been reported, several established and novel ASMs, some surgical strategies and other treatment approaches are of benefit or are showing promise. Progress remains incremental but any improvements in the management of this resistant epilepsy syndrome are worthwhile.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"15-27"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel techniques for early diagnosis and monitoring of Alzheimer's disease. 早期诊断和监测阿尔茨海默病的新技术。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-10-22 DOI: 10.1080/14737175.2024.2415985

Parul, Animesh Singh, Shubha Shukla

{"title":"Novel techniques for early diagnosis and monitoring of Alzheimer's disease.","authors":"Parul, Animesh Singh, Shubha Shukla","doi":"10.1080/14737175.2024.2415985","DOIUrl":"10.1080/14737175.2024.2415985","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is the most common neurodegenerative disorder, which is characterized by a progressive loss of cognitive functions. The high prevalence, chronicity, and multimorbidity are very common in AD, which significantly impair the quality of life and functioning of patients. Early detection and accurate diagnosis of Alzheimer's disease (AD) can stop the illness from progressing thereby postponing its symptoms. Therefore, for the early diagnosis and monitoring of AD, more sensitive, noninvasive, straightforward, and affordable screening tools are needed.Areas covered: This review summarizes the importance of early detection methods and novel techniques for Alzheimer's disease diagnosis that can be used by healthcare professionals.Expert opinion: Early diagnosis assists the patient and caregivers to understand the problem establishing reasonable goals and making future plans together. Early diagnosis techniques not only help in monitoring disease progression but also provide crucial information for the development of novel therapeutic targets. Researchers can plan to potentially alleviate symptoms or slow down the progression of Alzheimer's disease by identifying early molecular changes and targeting altered pathways.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"29-42"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The involvement of the microbiota-gut-brain axis in the pathophysiology of mood disorders and therapeutic implications. 微生物-肠-脑轴在情绪障碍病理生理中的作用及其治疗意义。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-08 DOI: 10.1080/14737175.2024.2438646

Izabela G Barbosa, Aline S Miranda, Michael Berk, Antonio L Teixeira

引用次数: 0

Why is the treatment and management of amyotrophic lateral sclerosis so difficult? 肌萎缩侧索硬化症的治疗和管理为何如此困难？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-10-11 DOI: 10.1080/14737175.2024.2415002

Philippe Corcia, Rachele Piras, Christian Lunetta

引用次数: 0

Treatment strategies for patients with spinal muscular atrophy. 脊髓性肌萎缩症的治疗策略。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-10 DOI: 10.1080/14737175.2024.2439486

Liesbeth De Waele, Laurent Servais

引用次数: 0

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence. 偏头痛的急性和预防性治疗：证据的叙述性回顾。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI: 10.1080/14737175.2024.2434079

Lars Edvinsson

{"title":"Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence.","authors":"Lars Edvinsson","doi":"10.1080/14737175.2024.2434079","DOIUrl":"10.1080/14737175.2024.2434079","url":null,"abstract":"Introduction: Rimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine.Areas covered: A brief overview of migraine, the pharmacokinetics of rimegepant, and the mechanism of action of rimegepant are provided. Evidence evaluating rimegepant as an acute or preventive treatment of migraine is then summarized in more detail, based on a literature search for full-length publications related to clinical or real-world use of rimegepant.Expert opinion: Several clinical trials established rimegepant as a safe and effective treatment (acute and preventive) of migraine in adults. There are few head-to-head studies with other migraine treatments to determine relative efficacy. However, the favorable safety profile of rimegepant makes it appropriate for many patients, particularly those with contraindication, intolerance, or inadequate response to other classes of standard-of-care migraine treatments. Additional studies on the efficacy and cost-effectiveness relative to other treatments may further define the role of rimegepant in migraine treatment.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1141-1155"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0